TP53 and neoplasm: Poor outcome has also been reported to be associated with older age at presentation (age 14 years or 18 years) [4], [6], [7], larger tumour volume [6], [8], [9], poor response to induction therapy [6], axial tumour localization [4], [6], elevated serum levels of lactate dehydrogenase [10], less than 90% necrosis after primary chemotherapy [11], deletion of p16 [12] and mutation of p53 proteins [13], [14].